Therapeutic area
  • Biotherapeutic
  • Cancer

What the technology does

A ligand trap that specifically blocks Ang-2 activity


A highly specific ligand trap for Ang2, evolved using a proprietary directed evolution technique, that does not block the protective activity of Ang1.

Main application field

Treatment of pathological angiogenesis, e.g. diabetic retinopathy.




Technology ready for evaluation and collaborative development2

Intellectual Property

Priority UK filing made 20/12/2012. PCT/GB2013/053392


Exclusive or non-exclusive licence

Key Contact

  • Hidden
  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
All Licensing Opportunities